Get the Stockscreener App
328.19
0.98%
-3.26
After Hours:
328.19
Madrigal Pharmaceuticals Inc stock is traded at $328.19, with a volume of 187.05K.
It is down -0.98% in the last 24 hours and up +50.69% over the past month.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
See More
Previous Close:
$331.45
Open:
$331.02
24h Volume:
187.05K
Relative Volume:
0.48
Market Cap:
$7.16B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-17.06
EPS:
-19.24
Net Cash Flow:
$-438.32M
1W Performance:
-5.54%
1M Performance:
+50.69%
6M Performance:
+47.49%
1Y Performance:
+66.29%
1-Day Range:
$323.50
$331.14
1-Week Range:
$323.50
$351.81
52-Week Range:
$168.25
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
328.19 | 7.16B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Braidwell LP Makes New $39.01 Million Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
MDGL (Madrigal Pharmaceuticals) EBITDA : $-502.65 Mil (TTM As of Sep. 2024) - GuruFocus.com
Vestal Point Capital LP Buys Shares of 30,000 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
1,852 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Blueshift Asset Management LLC - MarketBeat
MDGL (Madrigal Pharmaceuticals) Shares Outstanding (EOP) : 21.81 Mil (As of Sep. 2024) - GuruFocus.com
Advantage Alpha Capital Partners LP Acquires New Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
6,032 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Intech Investment Management LLC - MarketBeat
Madrigal Pharmaceuticals (LTS:0JXI) Total Stockholders Equi - GuruFocus.com
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move - MSN
Eagle Asset Management Inc. Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
MDGL (Madrigal Pharmaceuticals) Total Inventories : $8.72 Mil (As of Sep. 2024) - GuruFocus.com
When (MDGL) Moves Investors should Listen - Stock Traders Daily
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? - Zacks Investment Research
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Madrigal Pharmaceuticals Engages with Investors at Key Conferences - MSN
Connor Clark & Lunn Investment Management Ltd. Decreases Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal shares hold as Cowen maintains price target on new data - Investing.com Canada
Madrigal Pharmaceuticals (FRA:YDO1) Peter Lynch Fair Value : N/A (As of Nov. 20, 2024) - GuruFocus.com
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra (MDGL:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Reiterates Neutral Rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) - MarketBeat
Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH - Citeline
Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade - Yahoo Finance
(11/18/24) MDGL: A Promising Play in the Weight Loss Drug Space - Moneyshow.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $347.33 Average Target Price from Brokerages - MarketBeat
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
John Paulson's Strategic Acquisition in Madrigal Pharmaceuticals - GuruFocus.com
Janus Henderson Group PLC's Strategic Reduction in Madrigal Phar - GuruFocus.com
RTW INVESTMENTS, LP Expands Stake in Madrigal Pharmaceuticals Inc - GuruFocus.com
(MDGL) Trading Report - Stock Traders Daily
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More - AOL
Fiera Capital Corp Sells 3,535 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock - Investing.com India
3 High Growth Tech Stocks Leading The US Market - Simply Wall St
B. Riley Has Bullish Estimate for MDGL FY2024 Earnings - MarketBeat
Madrigal Pharmaceuticals (FRA:YDO1) Current Ratio : 5.98 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences - The Manila Times
Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan
Analysts Offer Predictions for MDGL Q1 Earnings - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares - Investing.com
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares By Investing.com - Investing.com UK
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
MDGL (Madrigal Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Check Out What Whales Are Doing With MDGL - Benzinga
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectat - GuruFocus.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):